



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Li et al.

Docket No.: PF126P2

Application No.: 09/901,910

Confirmation No.: 7856

Filed: July 11, 2001

Art Unit: 1635

For: Connective Tissue Growth Factor-2

Examiner: T. Gibbs

**SUPPLEMENTAL
INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

BEST AVAILABLE COPY

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references AH-AJ listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), because this Information Disclosure Statement is being submitted after the mailing date of the first Office Action on the merits, but before the mailing


BEST AVAILABLE COPY

date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Information Disclosure Statement if it is accompanied by the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the Patent & Trademark Office is hereby authorized to charge our Deposit Account No. 08-3425 in the amount of \$180.00 as payment of the required fee, as itemized on the Fee Transmittal Sheet submitted concurrently herewith. The Patent & Trademark Office is also authorized to charge any additional required fee or credit any overpayment in connection with this submission to our Deposit Account No. 08-3425.

Dated: December 23, 2003

Respectfully submitted,

By 
Mark J. Hyman

Registration No.: 46,789
HUMAN GENOME SCIENCES, INC.
9410 Key West Avenue
Rockville, Maryland 20850
(240) 314-1224

MJH/KN/ba



PTO/SB/08a/b (06-03)

Approved for use through 07/31/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/901,910-Conf. #7856
Filing Date	July 11, 2001
First Named Inventor	Haodong Li
Art Unit	1635
Examiner Name	T. Gibbs
Attorney Docket Number	PF126P2

BEST AVAILABLE COPY**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AH	PAKKANEN et al., "Gene Therapy for Atherosclerosis and Atherosclerosis-Related Diseases," <i>Current Atherosclerosis Rep.</i> , 1:123-130 (1999).	
	AI	DIAZ-SANDOVAL et al., "Gene therapy for cardiovascular angiogenesis," <i>Expert Opin. Biol. Ther.</i> , 3(4):599-616 (2003).	
	AJ	NIKOL et al., "Vascular Gene Therapy - Preclinical and Clinical Experience in Vascular Gene Therapy: Advantages Over Conservative/Standard Therapy," <i>J. Invas. Cardiol.</i> , 13:333-338 (2001).	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
-----------------------	--------------------